Activated B-cell (ABC) type diffuse large B-cell lymphoma (DLBCL) is a more aggressive form of the disease than non-ABC type DLBCL. Some DLBCL contain a mutated form of the CD79 gene. Both of these types of DLBCL have increased activity in certain cellular pathways that can promote tumor growth.
In this study, researchers are evaluating a combination of two drugs to treat ABC type DLBCL and CD79-mutant DLBCL. One is an investigational drug called AEB071, which works by inhibiting protein kinase C, an enzyme which fuels cancer growth. The other drug is everolimus, which inhibits cancer growth by targeting a protein called mTOR. Everolimus is approved for treating advanced kidney cancer, but its use for DLBCL is considered investigational.
Both AEB071 and everolimus are taken orally (by mouth).